Strontium (Sr) and related compounds have become more attractive in the prevention and
treatment of osteoporosis. Previously, we developed a novel bioactive bone cement, which mainly
composed of strontium-containing hydroxyapatite (Sr-HA) filler and bisphenol A diglycidylether
dimethacrylate (Bis-GMA) resin. This bone cement is superior to conventional
polymethylmethacrylate (PMMA) bone cement in bioactivity, biocompatibility, and osseointegration.
It also has shown sufficient mechanical strength properties for its use in percutaneous vertebroplasty
(PVP) and total hip replacement (THR). In this chapter, we reviewed the in vitro, in vivo, and clinical
evidence for the effectiveness of this bioactive bone cement.
